



# Editorial Report 2018 and 2019 YTD

# 5-year overview



<sup>\*2019</sup> data is a projection based on actual data as at 31/07/19

## Insights 2018 and 2019 YTD



2018: submissions increased by 12% over previous year.
Quality improved too.
Average weekly publications: 3 articles

2019\* peak of submissions, due to PubMed inclusion. By 31/07, 167 papers received, as much as in the whole 2018

<sup>\*2019</sup> data is a projection based on actual data as at 31/07/19

### **Publication Data**

Increase in submissions by +12%


Rejection rate is unchanged (50%).

In 2018, frequency of publication increased to **12** issues: one issue per month.

|                   | 2016 | 2017 | 2018 | 2019* | %    |
|-------------------|------|------|------|-------|------|
| Issues            | 7    | 10   | 12   | 12    |      |
| Articles x<br>Iss | 8    | 8    | 8    | 9-12  |      |
| Accepted          | 67   | 71   | 78   | 133   | +9%  |
| Published         | 61   | 64   | 84   | 145   | +31% |
| Submitted         | 120  | 145  | 162  | 286   | +12% |

<sup>\*2019</sup> data is a projection based on actual data as at 31/07/19

### Where do our articles come from?




### Processing time and performance

### Average time from:

| Peer Review                          |         |  |  |  |
|--------------------------------------|---------|--|--|--|
| Submission to first decision         | 9 days  |  |  |  |
| Production*                          |         |  |  |  |
| Final decision to online publication | 4 weeks |  |  |  |
| Total*                               |         |  |  |  |
| From submission to publication       | 6 weeks |  |  |  |

<sup>\*</sup>production time includes copyediting, author proof approval and check out payment.






**EJCRIM** is now fully indexed on **PubMed Central**Published articles starting from **2016** are included in PMC



### Web traffic

### Time spent on webpages

| Country     | Pg/Session | Avg Duration |
|-------------|------------|--------------|
| Total       | 2,62       | 00:02:13     |
| Austria     | 13,02      | 00:09:43     |
| Luxembourg  | 3,67       | 00:06:48     |
| Israel      | 3,81       | 00:06:34     |
| Italy       | 4,42       | 00:05:25     |
| Turkey      | 3,97       | 00:03:21     |
| Spain       | 3,50       | 00:03:16     |
| Portugal    | 3,97       | 00:03:21     |
| Switzerland | 3,78       | 00:02:57     |
| Belgium     | 2,94       | 00:02:46     |
| Germany     | 2,61       | 00:02:32     |



### Most read articles in 2018

- Morini et al. Severe milk-alcakali syndrome in a patient with hypoparathyroidism with 1,25(OH)2H, hidrochlorothiazide and anthranoid laxative consumption (2017)
- Ferreira et al. An itchy problem: a clinical cause of crusted scabies (2017)
- Malek et al. Chronic mercury intoxication masquerading as systemic disease: a case report and review of the literature (2017)
- Vesza et al. Statin related lichenoid dermatosis: an uncommon adverse reaction to a common treatment (2018)

### **Citations**

EJCRIM articles cited about 60 times. 10+ citations per year.

### The most cited article is still

von Wowern F, Brizzi M, Holst J. Reversal of the anticoagulation effects of dabigatran etexilate by idarucizumab in three patients needing urgent surgical intervention and one case of intravenous thrombolysis in ischaemic stroke. EJCRIM 2017;4.doi:10.12890/2017\_000569 that has been cited 5 times in a year.

The Journal that cites us most is Reactions Weekly by Springer.

### **Promotion**

# Monthly e-TOCs when an issue is published

- ✓ Table of contents and links to the issue
- ✓ Relevant news.
- ✓ Promotion of future events
- ✓ Featured articles

### **GDPR** caused a downfall in contacts

Interested in receiving the newsletter? Check the website or find us at the booth.

And our social channels...



#### EJCRIM: ECIM 2019 is coming up!

#### Our Volume 6, Issue 7 is online

We at EJCRIM we'll attend the 19th European Congress of Internal Medicine, that is going to be held in Lisbon, Portugal at the end of August. Are you attending as well? Find us at our booth in the exhibition area, come and chat manuscripts!

Moreover, if you submitted an abstract for ECIM 2019, it might be selected for the EJCRIM Case Report Competition and Award... but more on that later!

#### **FEATURED ARTICLE**



### Interstitial Lung Disease in a Patient Treated with Denosumab

Ana Campo Ruiz, Miguel F Carrascosa, Sergio Tapia Concha, Anibal Hernández Gil, Juan García Rivero

Denosumab is an antiresorptive agent widely used for treating osteoporosis. We present, to our knowledge, the first case report in the English literature of clinically

### Social EJCRIM

Facebook still plays an important role in the journal's circulation life.

Our audience seems to appreciate this outlet for newly published articles, forthcoming events and flash "useful news" and announcements. EJCRIM's facebook page has to date **2,700** spontaneous **likes**.

A Twitter account has been recently inaugurated. Follow us: @ejcrim

Future local events and conferences can be promoted through our social channels.

### **Future endeavours**

#### Involve **industries** in order to:

- ✓ publish cases collections
- ✓ Offer their KOLs the chance to publish free online
- ✓ advertise through banners

#### Liase more with national societies

- ✓ case reports competitions at your national event
- √ link exchanges
- ✓ promote your event through our channels
- √ book of abstract service

New types of articles?



ECIM's Abstract Book is edited by EJCRIM available <a href="https://www.ejcrim.com">www.ejcrim.com</a> in September

### New types of articles published

### Hospital Grand Rounds

- ✓ Topics discussed as Med School Grand Rounds
- ✓ Scouted by our Editorial Board Members
- ✓ Include a description of the Hospital
- ✓ 2 published since launch: 1 from Slovenia, 1 from Italy

Is it time for new types of articles?




### www.eurordis.org



### WHAT IS A RARE DISEASE?

### Prevalence rate of selected rare diseases worldwide as of 2017 (per 100,000 population)\*




Source Torreya Partners © Statista 2018 Additional Information: Worldwide; as of October 20 17





### 5 per 10,000 of the population Over 6000 diseases 6 and 8 % of the population affected


- around 80% of rare are genetic
- 80% of all rare disease patients are affected by 350 diseases.
- most life threatening or disabling
- around 50 to 75% of all rare diseases affect children
- around 30% of children with a rare disease die before their 5th birthday
- late diagnosis, absent diagnosis or incorrect diagnosis are commonplace

Sources: EURORDIS, 2005; Ayme & Hivertleds, 2011; Posada de la Paz & Croft, 2010; NCMG, 2010; French National Plan on Rare Diseases 2004-2008.











# Thank you!

But still ...
come and see us at the Journal's booth